MARKET

EXAS

EXAS

Exact Sciences Corp
NASDAQ
102.26
+0.01
+0.01%
After Hours: 102.24 -0.02 -0.02% 17:35 01/14 EST
OPEN
102.30
PREV CLOSE
102.25
HIGH
102.56
LOW
102.12
VOLUME
3.69M
TURNOVER
--
52 WEEK HIGH
102.66
52 WEEK LOW
38.81
MARKET CAP
19.41B
P/E (TTM)
-19.2327
1D
5D
1M
3M
1Y
5Y
1D
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises
NASDAQ · 1d ago
Tempus AI Stock Rallies 105% in a Year: Should Investors Still Hold?
NASDAQ · 2d ago
Weekly Report: what happened at EXAS last week (0105-0109)?
Weekly Report · 2d ago
Clinical Labs Hope to Head Off Looming Medicare Cuts
Barron‘s · 5d ago
Exact Sciences Sets February 20, 2026 Virtual Meeting for Shareholder Vote on $105-per-Share Abbott Merger
TipRanks · 5d ago
Abbott price target lowered to $152 from $157 at Goldman Sachs
TipRanks · 5d ago
CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois
NASDAQ · 6d ago
Exact Sciences: Abbott Acquisition A Positive Sign For Oncology Diagnostics
Seeking Alpha · 01/07 22:11
More
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Webull offers Exact Sciences Corp stock information, including NASDAQ: EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXAS stock methods without spending real money on the virtual paper trading platform.